Clinical Trial Imaging Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Clinical Trial Imaging Market 

5.1. COVID-19 Landscape: Clinical Trial Imaging Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Clinical Trial Imaging Market, By Service

8.1. Clinical Trial Imaging Market, by Service, 2024-2033

8.1.1 Clinical Trial Design and Consultation Services

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Reading and Analytical Services

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Project and Data Management

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. System and Technology Support Services

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Clinical Trial Imaging Market, By Modality

9.1. Clinical Trial Imaging Market, by Modality, 2024-2033

9.1.1. Computed Tomography

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Ultrasound

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Magnetic Resonance Imaging

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Positron Emission Tomography

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Echocardiography

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.6. X-Ray

9.1.6.1. Market Revenue and Forecast (2021-2033)

9.1.7. Other Modalities

9.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Clinical Trial Imaging Market, By End-Use 

10.1. Clinical Trial Imaging Market, by End-Use, 2024-2033

10.1.1. Pharmaceutical Companies

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Medical Device Manufacturers

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Academic and Government Research Institutes

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Biotechnology Companies

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Contract Research Organizations

10.1.5.1. Market Revenue and Forecast (2021-2033)

10.1.6. Other End-Users

10.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Clinical Trial Imaging Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Service (2021-2033)

11.1.2. Market Revenue and Forecast, by Modality (2021-2033)

11.1.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Service (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Modality (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Service (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Modality (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Service (2021-2033)

11.2.2. Market Revenue and Forecast, by Modality (2021-2033)

11.2.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Service (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Modality (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Service (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Modality (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Service (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Modality (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Service (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Modality (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Service (2021-2033)

11.3.2. Market Revenue and Forecast, by Modality (2021-2033)

11.3.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Service (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Modality (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Service (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Modality (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Service (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Modality (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Service (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Modality (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Service (2021-2033)

11.4.2. Market Revenue and Forecast, by Modality (2021-2033)

11.4.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Service (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Modality (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Service (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Modality (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Service (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Modality (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Service (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Modality (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Service (2021-2033)

11.5.2. Market Revenue and Forecast, by Modality (2021-2033)

11.5.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Service (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Modality (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End-Use (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Service (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Modality (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End-Use (2021-2033)

Chapter 12. Company Profiles

12.1. IXICO plc

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Intrinsic Imaging

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Resonance Health

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. BioTelemetry

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Navitas Life Sciences

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. ProScan Imaging

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Cardiovascular Imaging Technologies

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Medpace

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Radiant Sage LLC

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Biomedical Systems Corp

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms